MARIANNE FRIERI, Ph.D., M.D.; NICHOLAS M. PAPADOPOULOS, Ph.D.; MICHAEL A. KALINER, M.D.; DEAN D. METCALFE, M.D.
Systemic mastocytosis is a multisystem disease involving mast cell proliferation in the skin, bone, lymph nodes, liver, spleen, and gastrointestinal tract. When mast cell proliferation is limited to the skin, the disease is more benign and is termed urticaria pigmentosa. Patients with systemic mastocytosis experience numerous problems attributable to an excess of mast-cell-derived chemical mediators. These difficulties include pruritis, flushing, hypotension, and peptic ulcer disease among others (1). It has been suggested that one of the functions of mast cells may be the prevention of atherosclerosis due to the lipid-clearing actions of mast cell heparin (2). However, patients with systemic
FRIERI M, PAPADOPOULOS NM, KALINER MA, METCALFE DD. An Abnormal Pre-Beta Lipoprotein in Patients with Systemic Mastocytosis. Ann Intern Med. ;97:220–221. doi: 10.7326/0003-4819-97-2-220
Download citation file:
Published: Ann Intern Med. 1982;97(2):220-221.
Cardiology, Coronary Risk Factors, Dyslipidemia, Hematology/Oncology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use